Business Wire

ORAL-B

Share
Oral-B Encourages Consumers to Brush up on Their Oral Care Regimen and Recognise Its Importance to Overall Body Health

Oral-B has teamed up with Scientific American and its Custom Media Division (SACM) to explore the latest research connecting oral health and overall health; as many are unaware of the impact chronic periodontal diseases have on wider systemic disease.

The brand is leading the way in innovation, technology and research to help protect oral health and educate about the important connection between oral and overall body health. As part of the year-long partnership, Oral-B and Scientific American Custom Media are releasing a series of content, including educational resources from leading medical and dental researchers that will help readers better understand the connections between oral health and whole body health.

Oral diseases are at crisis level as it is estimated that they affect nearly 3.5 billion people worldwidei and in the midst of a global health pandemic, it is more crucial than ever to safeguard not only your oral health but your whole-body health too.

Jeremy A. Abbate, VP & Publisher at Scientific American explains: “Over 700 studies substantiate the notion that great oral health habits can be a simple step in improving one’s overall health. It’s proven that periodontitis increasingly poses a significant risk to the development and progression of multiple systemic conditions and gum disease is the mouth’s way of warning us of potentially more serious issues to come, so it’s important to heed those early warnings.”

While warning signs can be as small as bleeding gums or even tooth loss, they can lead to more severe conditions such as heightened pregnancy complications, cognitive loss, poor diabetes control, and increases the risk of cardiovascular disease.

SYSTEMIC SPREAD OF PLAQUE BACTERIA THROUGHOUT THE BODY

A healthy mouth has minimal plaque build-up, ensuring oral bacteria cannot multiply, cause cavities, gum deterioration or spread beyond the mouth. However, when plaque build-up is present around the gum line and between teeth, it shelters oral bacteria (including P.gingivalis) from your toothbrush and natural defences. This provides the perfect conditions for the bacteria to thrive and cause inflammation-causing toxins that are known to spread throughout the rest of the body.

The formation of gum disease begins when plaque containing millions of bacteria coats the teeth, accumulates undisturbed. Acid produced by the bacteria can erode tooth enamel causing cavities and irritate the gums and cause gingivitis which can progress into periodontitis – a more serious infection that can lead to tooth loss.

When oral conditions worsen, the hidden plaque bacteria can cause an inflammatory response in the periodontal tissues that sets off a chain reaction, spreading systemically through the body via the circulatory system to other parts of the body. These oral bacteria are also found to be transmitted via the lungs and gastrointestinal tract.

DISEASES IMPACTED BY GUM DISEASE

  1. StrokePeriodontitis may increase the risk for stroke. A continuous flow of bacteria into the bloodstream from exacerbated gum sites can trigger inflammation, prompting plaque growth and leading to blood clots.ii
  2. Diabetes - There is a two-way relationship between diabetes and periodontitis, with more severe periodontal tissue destruction observed in diabetic populations , due to poorly controlled glucose levels.iii iv
  3. Heart disease - Patients with periodontal disease are at increased risk for cardiovascular disease. Chronic gum inflammation may cause bad bacteria and toxins to enter the bloodstream and circulate to plaque sites in arterial walls.v
  4. Pregnancy gingivitis - Pregnant women are at increased risk of gingivitis and pregnant women with periodontitis are at increased risk for adverse pregnancy outcomes , including pre-term birth, low birth weight babies, and pregnancy hypertension (pre-eclampsia).vi
  5. Dementia - Patients with Alzheimer’s Disease and cognitive function loss have a higher risk for developing poor oral hygiene and periodontal disease. The relationship is bi-directional , as periodontal bacteria can also infect the brain and play a direct role in the build-up of amyloid brain lesions, leading to Alzheimer’s disease.vii

MAINTAINING A HEALTHY MOUTH AND BODY

Oral-B, the No.1 Dentist Recommended Toothbrush Brand Worldwide, is on a mission to make the invisible connection between oral health and whole-body wellness visible and to empower people to take their health into their own hands.

Following a daily holistic Oral-B regimen can help with maintaining a happy, healthy mouth:

  • Electric Toothbrush with a Round-Head
    Oral-B brushes are round for a reason, to adapt to each individual tooth and reach between the teeth. The Oral-B iO’s revolutionary technology removes 100% more plaque than a manual brush to give you that professional clean feeling every single day.
  • Stannous Fluoride Toothpaste
    Stannous Fluoride (SnF2) helps to protect your gums against bacterial plaque.
  • Mouth Rinse
    Mouth rinses containing bioavailable Cetylpyridinium Chloride (CPC) formulated at 0.07% helps to reduce plaque.
  • Interdental Cleaning
    Plaque easily accumulates and hides between teeth where toothbrushing can’t reach. Regular cleaning between teeth helps to remove plaque and helps protect gums.
  • Regular Oral-Health Check-Ups
    Partner with your dental professional regularly to prevent and detect signs of gum infection at its earliest stages.

Scientific American educational resources developed in partnership with Oral B can be found here.

####

About Oral-B

Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by Dr. Robert Hutson, a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Artificial Intelligencery®, Febreze®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.


i Oral Health https://www.who.int/news-room/fact-sheets/detail/oral-health (Accessed April 2021)

ii Janket SJ, Baird AE, Chuang SK, Jones JA. Meta- analysis of periodontal disease and risk for coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:559-569

iii Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: A two-way relationship. Ann Periodontol 1998;3:51-61

iv Preshaw PM, Alba AL, Jepsen S, Konstantinidis A, Makrilakis K, Taylor R. Periodontitis and diabetes: A two-way relationship. Diabetologia 2012;55:21-31.

v Blaizot A, Vergenes JN, Nuwwareh S, Amar J, Sixou M. Periodontal diseases and cardiovascular events: Meta-analyseis of observational studies. Int Dent J 2009; 59(4):197-209

vi Daalderop LD,Wieland BV, Tomsin K, Reyes L, Kramer BW, Vanterpool SF. Periodontal disease and pregnancy outcomes: Overview of systematic reviews. JDR Clinl Transl Res 2018;3:10-27. | Manrique-Corredor EJ, Orozco-Beltran D, Lopez-Pineda A, Quesada JA, Gil-Guillen VF, Carratala-Munuera C. Maternal periodontitis and preterm birth: systematic review and meta-analysis. Community Dent Oral Epidemiol 2019;47:243-251. | Chambrone L, Guglielmetti MR, Pannati CM, Chambrone LA. Evidence grade associating periodontitis to preterm birth and/or low birth weight: I. A systematic review of prospective cohort studies. J Clin Periodontol 2011;38:795-808. | Wei BJ, Chen YJ, Wu B. Periodontal disease and risk of preeclampsia: A meta- analysis of observational studies. PLOS ONE 2013;8:1-6. | Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: Systematic review and meta-analysis. Am J Obstet Gynecol. 2008;Jan:7-22

vii Savitt ED, Socransky SS. Distribution of certain subgingival microbial species in selected periodontal conditions. J Periodontal Res 1984, 19 (2): 111-123.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Philip Morris International Publishes Updated Climate Transition Plan to Achieve Net Zero by 20403.11.2025 11:00:00 CET | Press release

The plan details actions, timelines, and targets for climate change mitigation and adaptation in the company’s direct operations and the most vulnerable areas of its supply chain Philip Morris International Inc. (PMI) (NYSE: PM) today announced the release of its second Climate Transition Plan (CTP 2025), presenting an updated and integrated strategy to achieve net-zero greenhouse gas (GHG) emissions across its value chain by 2040. The new plan reflects PMI’s continued commitment to a low-carbon future while aligning with science, regulatory frameworks, and stakeholder expectations, and builds on its 2021 Low-Carbon Transition Plan. Further, building on its 2022 Task Force on Climate-related Financial Disclosures (TCFD) report, the CTP 2025 details the results of a comprehensive climate change risks and opportunities (CCRO) assessment PMI conducted in 2024. “This Climate Transition Plan reinforces our commitment to sustainability as a fundamental business driver at PMI—one that is inte

SLB Unveils Groundbreaking New Agentic AI Technology for the Energy Industry3.11.2025 11:00:00 CET | Press release

Global energy technology company SLB (NYSE: SLB) today announced the launch of Tela™, an agentic AI assistant purpose-built to transform the upstream energy sector. Tela leverages agentic AI to not only automate processes but transform workflows and drive better business outcomes. Tela will be embedded in SLB’s portfolio of applications and platforms, and users will interact through a simple conversational interface. This approach enables agentic AI to act as a proactive collaborator — augmenting the workforce to achieve greater productivity and efficiency at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103326704/en/ Tela follows a common five-step agentic AI loop: observe, plan, generate, act and learn. This allows agents within Tela to proactively interact with their environment, adapt to new data, and continuously improve outcomes. Whether interpreting well logs, predicting drilling issues, or optimizing equip

KCAS Bio Strengthens Board of Directors with Appointment of Paul Kirchgraber and Kurt Doyle3.11.2025 09:30:00 CET | Press release

KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio’s continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites in the greater Philadelphia area; Lyon, France; and a partnership in Melbourne, Australia. The Company is backed by Vitruvian Partners, one of the world’s leading growth-focused investment firms. Dr. Paul Kirchgraber brings decades of leadership experience in clinical research and laboratory operations. He served as Executive Vice President and CEO of Covance, Labcorp’s Drug Development Division, where he led global teams in drug and medical device development in over 60 countries. Dr. Kirchgraber has experience running global p

Eric Jing: Ant Group to Strengthen Support for Hong Kong's Global Finance and Tech Leadership with AI, GoGlobal Services3.11.2025 09:19:00 CET | Press release

Eric Jing, Chairman of Ant Group, reaffirmed Ant’s commitment to deepening cross-sector collaboration on regulated AI and tokenization innovation in the territory, and to expanding its cross-border payment and trade financing services to support Hong Kong’s initiative to help Chinese businesses go global. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251102787084/en/ John Lee, Chief Executive of Hong Kong SAR visited the booths of Ant International and Ant Digital Technologies during the 10th annual Hong Kong Fintech Week on November 3, 2025. Speaking on a panel with Christopher Hui, Hong Kong’s Secretary for Financial Services and the Treasury, and Fred Hu, Founder, Chairman and CEO of Primavera Capital Group at the 10th annual Hong Kong Fintech Week on November 3, 2025, Jing said the City’s visionary and prudent approach to policy innovation, rich commercial and financial use cases and a robust ecosystem of cross-sector c

Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region3.11.2025 09:00:00 CET | Press release

Julie Dehaene-Puype joins Kyowa Kirin as new President of the International RegionJeremy Morgan will retire at the end of December 2025 after a two-month leadership transition period Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty Pharmaceutical Company, today announced the appointment of Julie Dehaene-Puype as President for the Region, effective 1 November 2025. Julie follows the tenure of Jeremy Morgan, who has served as President for the International Region since 2023. Morgan will serve in an advisor role to the business through to the end of 2025, working in partnership with Dehaene-Puype to ensure a successful and smooth change for the company. “We are very pleased to welcome Julie to the company in the role as President of KKI,” said Tomohiro Sudo, Chief International Business Officer of Kyowa Kirin. “Julie joins us with extensive experience in global biotech and pharma spanning a 25-year caree

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye